Safety and Immunogenicity of Clade C ALVAC and gp120 HIV Vaccine (HVTN107)
A Phase 1/2a Partially Double-blinded, Randomized Clinical Trial to Characterize the Safety and Immunogenicity of Clade C ALVAC-HIV (vCP2438) and Bivalent Subtype C gp120 Alone, With MF59 Adjuvant, and With Alum Adjuvant in Healthy, HIV-uninfected Adult Participants
Sponsor: GlaxoSmithKline
A PHASE1/PHASE2 clinical study on HIV Infections, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 14 data snapshots since 2017. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
14 versions recorded-
Oct 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Apr 2024 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jul 2023 — Apr 2024 [monthly]
Completed PHASE1_PHASE2
▶ Show 9 earlier versions
-
Feb 2023 — Jul 2023 [monthly]
Completed PHASE1_PHASE2
-
Mar 2022 — Feb 2023 [monthly]
Completed PHASE1_PHASE2
-
Jan 2022 — Mar 2022 [monthly]
Completed PHASE1_PHASE2
-
Dec 2021 — Jan 2022 [monthly]
Completed PHASE1_PHASE2
-
Mar 2021 — Dec 2021 [monthly]
Completed PHASE1_PHASE2
-
Jan 2021 — Mar 2021 [monthly]
Completed PHASE1_PHASE2
-
Mar 2020 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2019 — Mar 2020 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Oct 2017 — Sep 2019 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Jun 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
- HIV Vaccine Trials Network
- National Institute of Allergy and Infectious Diseases (NIAID)
- Sanofi Pasteur, a Sanofi Company
For direct contact, visit the study record on ClinicalTrials.gov .